Shijubou N, Sumi T, Yamada Y, Nakata H, et al. Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer. J Cancer Res Clin Oncol 2022 Apr 9. pii: 10.1007/s00432-022-03941.
PMID: 35397688